These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15156302)

  • 41. Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
    Mustafa S; Yusuf WN; Woillard JB; Choon TS; Hassan NB
    Eur J Clin Pharmacol; 2016 Jul; 72(7):831-8. PubMed ID: 27025609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
    Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
    Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Race is not associated with nevirapine pharmacokinetics.
    de Maat MM; Nellen JF; Huitema AD; Wit FW; Mulder JW; Prins JM; Beijnen JH
    Ther Drug Monit; 2004 Aug; 26(4):456-8. PubMed ID: 15257078
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic interaction between nevirapine and nortriptyline in rats: inhibition of nevirapine metabolism by nortriptyline.
    Usach I; Melis V; Gandía P; Peris JE
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7041-8. PubMed ID: 25224004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
    Lee YC; Lin SW; Chen MY; Chang SY; Kuo CH; Sheng WH; Hsieh SM; Sun HY; Chang HY; Wu MR; Liu WC; Wu PY; Yang SP; Zhang JY; Su YC; Luo YZ; Hung CC; Chang SC
    PLoS One; 2015; 10(10):e0140574. PubMed ID: 26465325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.
    Zhang C; Wang W; Zhou M; Han Y; Xie J; Qiu Z; Guo F; Li Y; Wang H; Ghanem KG; Li T
    J Acquir Immune Defic Syndr; 2013 Apr; 62(5):540-5. PubMed ID: 23288032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
    Colafigli M; Di Giambenedetto S; Bracciale L; Fanti I; Prosperi M; Cauda R; De Luca A
    HIV Med; 2009 Sep; 10(8):461-9. PubMed ID: 19459991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
    Manosuthi W; Chumpathat N; Chaovavanich A; Sungkanuparph S
    BMC Infect Dis; 2005 Aug; 5():67. PubMed ID: 16120209
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
    Podzamczer D; Olmo M; Sanz J; Boix V; Negredo E; Knobel H; Domingo P; Pineda JA; Vilades C; Quero JH; Force L; Lahoz JG; Muñoz P; Llibre JM; Mariño A; Ortega E; Dalmau D; Gatell JM; Antón E; Sola J; Galindo MJ; Pedrol E; Sanz J; Lima JT; Flores J;
    J Acquir Immune Defic Syndr; 2009 Apr; 50(4):390-6. PubMed ID: 19214120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
    Decloedt EH; Mwansa-Kambafwile J; van der Walt JS; McIlleron H; Denti P; Smith P; Wiesner L; Rangaka M; Wilkinson RJ; Maartens G
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):333-5. PubMed ID: 23407222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of anticoagulants on plasma nevirapine and efavirenz concentrations.
    Hemanth Kumar AK; Ramachandran G; Kumar P; Anitha S; Rajasekaran S; Swaminathan S
    Ther Drug Monit; 2007 Oct; 29(5):652-4. PubMed ID: 17898659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nevirapine extended-release for the treatment of HIV-1 infection.
    Bogner JR
    Expert Rev Anti Infect Ther; 2012 Jan; 10(1):21-30. PubMed ID: 22149611
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.
    Wang J; Kou H; Fu Q; Han Y; Qiu Z; Zuo L; Li Y; Zhu Z; Ye M; Ma Q; Li T
    PLoS One; 2011; 6(10):e26739. PubMed ID: 22066007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
    Vreeman RC; Nyandiko WM; Liechty EA; Busakhala N; Bartelink IH; Savic RM; Scanlon ML; Ayaya SO; Blaschke TF
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):277-86. PubMed ID: 25140906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of nevirapine dosing recommendations in HIV-infected children.
    Foissac F; Bouazza N; Frange P; Blanche S; Faye A; Lachassinne E; Dollfus C; Hirt D; Benaboud S; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2013 Jul; 76(1):137-44. PubMed ID: 23278548
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
    Parienti JJ; Peytavin G
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):495-503. PubMed ID: 21417819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.